165 related articles for article (PubMed ID: 35955791)
21. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series.
Luedtke A; Boschmann M; Colpe C; Engeli S; Adams F; Birkenfeld AL; Haufe S; Rahn G; Luft FC; Schmidt HH; Jordan J
Horm Metab Res; 2012 Apr; 44(4):306-11. PubMed ID: 22274718
[TBL] [Abstract][Full Text] [Related]
22. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy.
Araújo-Vilar D; Lattanzi G; González-Méndez B; Costa-Freitas AT; Prieto D; Columbaro M; Mattioli E; Victoria B; Martínez-Sánchez N; Ramazanova A; Fraga M; Beiras A; Forteza J; Domínguez-Gerpe L; Calvo C; Lado-Abeal J
J Med Genet; 2009 Jan; 46(1):40-8. PubMed ID: 18805829
[TBL] [Abstract][Full Text] [Related]
23. Irisin levels in LMNA-associated partial lipodystrophies.
Bensmaïne F; Benomar K; Espiard S; Vahe C; Le Mapihan K; Lion G; Lemdani M; Chazard E; Ernst O; Vigouroux C; Pigny P; Vantyghem MC
Diabetes Metab; 2019 Jan; 45(1):67-75. PubMed ID: 30165155
[TBL] [Abstract][Full Text] [Related]
24. Severe loss of adipose tissue in a Vietnamese lipodystrophy patient caused by
Vu NP; Tran HT; Vu NB; Ma TTH; Nguyen TD; Nong HV; Nguyen HH
J Pediatr Endocrinol Metab; 2022 Sep; 35(9):1206-1210. PubMed ID: 35822709
[TBL] [Abstract][Full Text] [Related]
25. Histological and molecular features of lipomatous and nonlipomatous adipose tissue in familial partial lipodystrophy caused by LMNA mutations.
Araújo-Vilar D; Victoria B; González-Méndez B; Barreiro F; Fernández-Rodríguez B; Cereijo R; Gallego-Escuredo JM; Villarroya F; Pañeda-Menéndez A
Clin Endocrinol (Oxf); 2012 Jun; 76(6):816-24. PubMed ID: 21883346
[TBL] [Abstract][Full Text] [Related]
26. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy.
Araújo-Vilar D; Lado-Abeal J; Palos-Paz F; Lattanzi G; Bandín MA; Bellido D; Domínguez-Gerpe L; Calvo C; Pérez O; Ramazanova A; Martínez-Sánchez N; Victoria B; Costa-Freitas AT
Clin Endocrinol (Oxf); 2008 Jul; 69(1):61-8. PubMed ID: 18031308
[TBL] [Abstract][Full Text] [Related]
27. LMNA missense mutations causing familial partial lipodystrophy do not lead to an accumulation of prelamin A.
Tu Y; Sánchez-Iglesias S; Araújo-Vilar D; Fong LG; Young SG
Nucleus; 2016 Sep; 7(5):512-521. PubMed ID: 27841971
[TBL] [Abstract][Full Text] [Related]
28. High-throughput Second-generation Sequencing Technology Assisted Diagnosis of Familial Partial Lipodystrophy (Type 2 Kobberling-Dunnigan Syndrome): A Case Report.
Deng M; Chen W; Qi Y
Comb Chem High Throughput Screen; 2024; 27(2):346-351. PubMed ID: 37231758
[TBL] [Abstract][Full Text] [Related]
29. Clinical Spectrum of
Fernandez-Pombo A; Diaz-Lopez EJ; Castro AI; Sanchez-Iglesias S; Cobelo-Gomez S; Prado-Moraña T; Araujo-Vilar D
Cells; 2023 Feb; 12(5):. PubMed ID: 36899861
[TBL] [Abstract][Full Text] [Related]
30. Familial partial lipodystrophy presenting as metabolic syndrome.
Chan D; McIntyre AD; Hegele RA; Don-Wauchope AC
J Clin Lipidol; 2016; 10(6):1488-1491. PubMed ID: 27919367
[TBL] [Abstract][Full Text] [Related]
31. Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2; MIM 151660).
Lanktree M; Cao H; Rabkin SW; Hanna A; Hegele RA
Clin Genet; 2007 Feb; 71(2):183-6. PubMed ID: 17250669
[No Abstract] [Full Text] [Related]
32. Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence.
Caron M; Auclair M; Donadille B; Béréziat V; Guerci B; Laville M; Narbonne H; Bodemer C; Lascols O; Capeau J; Vigouroux C
Cell Death Differ; 2007 Oct; 14(10):1759-67. PubMed ID: 17612587
[TBL] [Abstract][Full Text] [Related]
33. A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies.
Treiber G; Flaus Furmaniuk A; Guilleux A; Medjane S; Bonfanti O; Schneebeli S; Bernard C; Le-Moullec N; Bakiri F; Pholsena M; Rollot O; Vatier C; Jarlet E; Jéru I; Lascols O; Darcel F; Domun B; Venault A; Venault S; Jacquemont ML; Doray B; Maiza JC; Cogne M; Vigouroux C; Nobécourt E
Eur J Endocrinol; 2021 Aug; 185(4):453-462. PubMed ID: 34292171
[TBL] [Abstract][Full Text] [Related]
34.
Jeru I; Vatier C; Vantyghem MC; Lascols O; Vigouroux C
J Med Genet; 2017 Jun; 54(6):413-416. PubMed ID: 28408391
[TBL] [Abstract][Full Text] [Related]
35. The retinol acid receptor B gene is hypermethylated in patients with familial partial lipodystrophy.
Cortese R; Eckhardt F; Volleth M; Wehnert M; Koelsch U; Wieacker P; Brune T
J Mol Endocrinol; 2007 Jun; 38(6):663-71. PubMed ID: 17556535
[TBL] [Abstract][Full Text] [Related]
36. Case Report: An Atypical Form of Familial Partial Lipodystrophy Type 2 Due to Mutation in the Rod Domain of Lamin A/C.
Cecchetti C; D'Apice MR; Morini E; Novelli G; Pizzi C; Pagotto U; Gambineri A
Front Endocrinol (Lausanne); 2021; 12():675096. PubMed ID: 33953703
[TBL] [Abstract][Full Text] [Related]
37. LMNA mutations, skeletal muscle lipid metabolism, and insulin resistance.
Boschmann M; Engeli S; Moro C; Luedtke A; Adams F; Gorzelniak K; Rahn G; Mähler A; Dobberstein K; Krüger A; Schmidt S; Spuler S; Luft FC; Smith SR; Schmidt HH; Jordan J
J Clin Endocrinol Metab; 2010 Apr; 95(4):1634-43. PubMed ID: 20130076
[TBL] [Abstract][Full Text] [Related]
38. [Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia].
Sorkina EL; Kalashnikova MF; Melnichenko GA; Tyulpakov AN
Ter Arkh; 2015; 87(3):83-87. PubMed ID: 26027246
[TBL] [Abstract][Full Text] [Related]
39. Molecular and Mechanobiological Pathways Related to the Physiopathology of FPLD2.
Varlet AA; Helfer E; Badens C
Cells; 2020 Aug; 9(9):. PubMed ID: 32842478
[TBL] [Abstract][Full Text] [Related]
40. The R439C mutation in LMNA causes lamin oligomerization and susceptibility to oxidative stress.
Verstraeten VL; Caputo S; van Steensel MA; Duband-Goulet I; Zinn-Justin S; Kamps M; Kuijpers HJ; Ostlund C; Worman HJ; Briedé JJ; Le Dour C; Marcelis CL; van Geel M; Steijlen PM; van den Wijngaard A; Ramaekers FC; Broers JL
J Cell Mol Med; 2009 May; 13(5):959-71. PubMed ID: 19220582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
